CPA2: A Potential Drug Target and Biomarker for Carboxypeptidase A2 (Pancreatic)

Target Name: CPA2

NCBI ID: G1358

CPA2

Other Name(s): carboxypeptidase A2 (pancreatic) | Carboxypeptidase A2 | CBPA2_HUMAN | carboxypeptidase A2

CPA2: A Potential Drug Target and Biomarker for Carboxypeptidase A2 (Pancreatic)

Pancreatic cancer is a leading cause of cancer-related deaths worldwide, with a five-year survival rate of only 12%. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes to aid in digestion. Carboxypeptidase A2 (CPA2) is a protein produced by the pancreas that helps break down certain proteins called peptides. Currently, there are no FDA-approved drugs that specifically target CPA2 in pancreatic cancer. This article discusses the potential drug target and biomarker for CPA2 in pancreatic cancer.

The Potential Role of CPA2 as a Drug Target

CPA2 has been identified as a potential drug target in pancreatic cancer due to its unique structure and its involvement in the disease process. CPA2 is a cytoplasmic protein that consists of 154 amino acids. It is expressed in all tissues of the body, including the pancreas, and has been shown to be involved in a variety of cellular processes.

One of the key functions of CPA2 is its role in the degradation of peptides. Peptides are short chains of amino acids that are involved in many cellular processes, including signaling and inflammation. CPA2 has been shown to break down a specific type of peptide called pro-inflammatory peptide-1 (PIP-1). PIP-1 is a potent activator of the NF-kappa-B signaling pathway, which is involved in inflammation and other cellular processes.

CPA2 has also been shown to play a role in cell survival and angiogenesis. It has been shown to promote the growth and survival of pancreatic cancer cells, and it has been shown to contribute to the development of new blood vessels in the tumor.

The Potential Role of CPA2 as a Biomarker

CPA2 has also been identified as a potential biomarker for pancreatic cancer. The diagnosis of pancreatic cancer is typically made through a combination of biopsy, imaging, and other clinical tests. Currently, there are no biomarkers that can be used to accurately predict the outcomes of pancreatic cancer patients. However, CPA2 has been shown to be a potential biomarker for pancreatic cancer.

One of the key reasons for the potential of CPA2 as a biomarker is its expression in the pancreas, which is the site of pancreatic cancer. This means that changes in CPA2 expression levels in the pancreas could be an indication of pancreatic cancer. Additionally, CPA2 has been shown to be overexpressed in pancreatic cancer, which could be an indication that it is a useful biomarker for this disease.

Conclusion

CPA2 is a protein produced by the pancreas that has been shown to be involved in a variety of cellular processes. Its potential as a drug target and biomarker for pancreatic cancer makes it an attractive target for future research. Further studies are needed to determine the exact role of CPA2 in pancreatic cancer and to develop biomarkers that can accurately predict the outcomes of pancreatic cancer patients.

Protein Name: Carboxypeptidase A2

The "CPA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets